|
| Interactions: | AcenocoumarolAdverse Effect: an increased risk of bleeding
Clinical Management: In patients receiving oral anticoagulation, the prothrombin time (PT) or international normalized ratio (INR) should be closely monitored with the addition and withdrawal of treatment with nonsteroidal antiinflammatory drugs (NSAIDs), including fenoprofen. Coagulation parameters should also be reassessed periodically during concurrent therapy. Adjustments of the acenocoumarol dose may be necessary in order to maintain the desired level of anticoagulation
AmilorideAdverse Effect: Reduced diuretic effectiveness, hyperkalemia, or possible nephrotoxicity Clinical Management: When administering Flurbiprofen and Amiloride concurrently, monitor the patient for decreased effectiveness of the diuretic and hyperkalemia. Monitor blood pressure, weight changes, urine output, potassium levels, and creatinine levels.
AmlodipineAdverse Effect:An increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Ardeparin Adverse Effect: an increased risk of bleeding and an increased risk of hematoma when neuraxial anesthesia is employed
Clinical Management: Patients receiving Ardeparin and Flurbiprofen concurrently should be monitored closely for bleeding, which may be serious. Gastrointestinal bleeding is a particular concern with this combination, as is the development of a spinal or epidural hematoma in patients who receive epidural/spinal anesthesia or spinal puncture prior to Ardeparin . Flurbiprofen should be discontinued several days prior to surgery.
Atenolol Adverse Effect: Decreased antihypertensive effect
Clinical Management: If concurrent therapy is required, monitor the patients blood pressure carefully and assess the need for a dosage adjustment for the beta blocker.
BenazeprilAdverse Effect: Decreased antihypertensive and natriuretic effects
Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.
Betaxolol Adverse Effect: Decreased antihypertensive effect
Clinical Management: If concurrent therapy is required, monitor the patients blood pressure carefully and assess the need for a dosage adjustment for the beta blocker.
Bisoprolol Adverse Effect: Decreased antihypertensive effect
Clinical Management: If concurrent therapy is required, monitor the patients blood pressure carefully and assess the need for a dosage adjustment for the beta blocker.
Bumetanide Adverse Effect: decreased diuretic and antihypertensive efficacy
Clinical Management: When administering loop diuretics and nonsteroidal antiinflammatory agents (NSAIDs) concurrently, monitor blood pressure and weight. Also, follow the patient for decreased urine output and increased edema.
CaptoprilAdverse Effect: Decreased antihypertensive and natriuretic effects
Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.
CarvedilolAdverse Effect: Decreased antihypertensive effect
Clinical Management: If concurrent therapy is required, monitor the patients blood pressure carefully and assess the need for a dosage adjustment for the beta blocker.
Celiprolol Adverse Effect: Decreased antihypertensive effect
Clinical Management: If concurrent therapy is required, monitor the patients blood pressure carefully and assess the need for a dosage adjustment for the beta blocker.
Chlorpropamide Adverse Effect: a possible increased risk of hypoglycemia
Clinical Management: When Flurbiprofen is coadministered with Chlorpropamide , patients should be monitored more closely for hypoglycemia. Dose of Chlorpropamide may need to be reduced when Flurbiprofen is added to therapy.
ChlorthalidoneAdverse Effect: Decreased diuretic and antihypertensive efficacy
Clinical Management: When administering thiazide diuretics and nonsteroidal antiinflammatory agents (NSAIDs) concurrently, monitor blood pressure and weight. Also, follow the patient for decreases in urine output and increased edema.
Clopamide Adverse Effect: Decreased diuretic and antihypertensive efficacy
Clinical Management: When administering thiazide diuretics and nonsteroidal antiinflammatory agents (NSAIDs) concurrently, monitor blood pressure and weight. Also, follow the patient for decreases in urine output and increased edema.
DalteparinAdverse Effect: an increased risk of bleeding and an increased risk of hematoma when neuraxial anesthesia is employed
Clinical Management: Patients receiving a low molecular weight heparin and a nonsteroidal antiinflammatory agent (NSAID) concurrently should be monitored closely for bleeding, which may be serious. Gastrointestinal bleeding is a particular concern with this combination, as is the development of a spinal or epidural hematoma in patients who receive epidural/spinal anesthesia or spinal puncture prior to low molecular weight heparin therapy. NSAID therapy should be discontinued several days prior to surgery.
DiltiazemAdverse Effect: An increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Enalapril Adverse Effect: Decreased antihypertensive and natriuretic effects
Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.
Enoxaparin Adverse Effect: an increased risk of bleeding and an increased risk of hematoma when neuraxial anesthesia is employed
Clinical Management: Patients receiving a low molecular weight heparin and a nonsteroidal antiinflammatory agent (NSAID) concurrently should be monitored closely for bleeding, which may be serious. Gastrointestinal bleeding is a particular concern with this combination, as is the development of a spinal or epidural hematoma in patients who receive epidural/spinal anesthesia or spinal puncture prior to low molecular weight heparin therapy. NSAID therapy should be discontinued several days prior to surgery.
Esmolol Adverse Effect: Decreased antihypertensive effect
Clinical Management: If concurrent therapy is required, monitor the patients blood pressure carefully and assess the need for a dosage adjustment for the beta blocker.
Felodipine Adverse Effect: An increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Flunarizine Adverse Effect: An increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
FrusemideAdverse Effect: Decreased diuretic and antihypertensive efficacy
Clinical Management: When administering Frusemide and Flurbiprofen concurrently, monitor blood pressure and weight. Also, follow the patient for decreased urine output and increased edema.
GlibenclamideAdverse Effect: A possible increased risk of hypoglycemia
Clinical Management: When Flurbiprofen is coadministered with Glibenclamide, patients should be monitored more closely for hypoglycemia. Dose of Glibenclamide may need to be reduced when Flurbiprofen is added to therapy.
Gliclazide Adverse Effect: a possible increased risk of hypoglycemia
Clinical Management: When nonsteroidal antiinflammatory agents (NSAIDs) are coadministered with a sulfonylurea drug, patients should be monitored more closely for hypoglycemia. Doses of the sulfonylurea may need to be reduced when NSAIDs are added to therapy.
GlimepirideAdverse Effect: a possible increased risk of hypoglycemia
Clinical Management: When nonsteroidal antiinflammatory agents (NSAIDs) are coadministered with a sulfonylurea drug, patients should be monitored more closely for hypoglycemia. Doses of the sulfonylurea may need to be reduced when NSAIDs are added to therapy.
Glipizide Adverse Effect: a possible increased risk of hypoglycemia
Clinical Management: When Flurbiprofen is coadministered with Glipizide , patients should be monitored more closely for hypoglycemia. Doses of Glipizide may need to be reduced when Flurbiprofen is added to therapy.
Indapamide Adverse Effect: Decreased diuretic and antihypertensive efficacy
Clinical Management: When administering thiazide diuretics and nonsteroidal antiinflammatory agents (NSAIDs) concurrently, monitor blood pressure and weight. Also, follow the patient for decreases in urine output and increased edema.
KetorolacAdverse Effect: enhanced gastrointestinal adverse effects (peptic ulcers, gastrointestinal bleeding and/or perforation)
Clinical Management: Concomitant use of ketorolac and other nonsteroidal antiinflammatory agents is contraindicated.
LMWH sod.salt Adverse Effect: Increased risk of bleeding and hematoma when neuraxial anesthesia is employed Clinical Management: Patients receiving LMWH sod.salt and Flurbiprofen concurrently should be monitored closely for bleeding, which may be serious. Gastrointestinal bleeding is a particular concern with this combination, as is the development of a spinal or epidural hematoma in patients who receive epidural-spinal anesthesia or spinal puncture prior to low molecular weight heparin therapy.
Labetalol Adverse Effect: Decreased antihypertensive effect
Clinical Management: If concurrent therapy is required, monitor the patients blood pressure carefully and assess the need for a dosage adjustment for the beta blocker.
LacidipineAdverse Effect: An increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
LevobunololAdverse Effect: Decreased antihypertensive effect
Clinical Management: If concurrent therapy is required, monitor the patients blood pressure carefully and assess the need for a dosage adjustment for the beta blocker.
LisinoprilAdverse Effect: Decreased antihypertensive and natriuretic effects
Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.
LithiumAdverse Effect: Lithium toxicity (weakness, tremor, excessive thirst, confusion)
Clinical Management: Serum lithium levels should be monitored within the first few days if a nonsteroidal antiinflammatory drug is added or discontinued from therapy, and periodically thereafter. Patients should be followed for any symptoms of toxicity; a decrease in the lithium dose is often required with concomitant therapy.
Methotrexate Adverse Effect: methotrexate toxicity (leukopenia, thrombocytopenia, anemia, nephrotoxicity, mucosal ulcerations)
Clinical Management: In general, do not administer NSAIDS within 10 days of high-dose methotrexate (ie, doses used in cancer therapy).
Metoprolol Adverse Effect: Decreased antihypertensive effect
Clinical Management: If concurrent therapy is required, monitor the patients blood pressure carefully and assess the need for a dosage adjustment for the beta blocker.
NadroparinAdverse Effect: an increased risk of bleeding and an increased risk of hematoma when neuraxial anesthesia is employed
Clinical Management: Patients receiving a low molecular weight heparin and a nonsteroidal antiinflammatory agent (NSAID) concurrently should be monitored closely for bleeding, which may be serious. Gastrointestinal bleeding is a particular concern with this combination, as is the development of a spinal or epidural hematoma in patients who receive epidural/spinal anesthesia or spinal puncture prior to low molecular weight heparin therapy. NSAID therapy should be discontinued several days prior to surgery.
Nifedipine Adverse Effect: An increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Nimodipine Adverse Effect: an increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent Flurbiprofen and Nimodipine should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
NitrendipineAdverse Effect: An increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Ofloxacin Adverse Effect: an increased risk of seizures
Clinical Management: Ofloxacin should be used cautiously in patients receiving other medications which may lower the seizure threshold, including nonsteroidal antiinflammatory drugs (NSAIDs). Alternative therapy should be considered, especially in patients who are predisposed to seizure activity.
Oxprenolol Adverse Effect: Decreased antihypertensive effect
Clinical Management: If concurrent therapy is required, monitor the patients blood pressure carefully and assess the need for a dosage adjustment for the beta blocker.
PerindoprilAdverse Effect: Decreased antihypertensive and natriuretic effects
Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.
PhenindioneAdverse Effect: An increased risk of bleeding
Clinical Management: In patients receiving Phenindione , the prothrombin time (PT) or international normalized ratio (INR) should be closely monitored with the addition and withdrawal of treatment with Flurbiprofen . Coagulation parameters should also be reassessed periodically during concurrent therapy. Adjustments of the phenindione dose may be necessary in order to maintain the desired level of anticoagulation. Clinicians and patients should be aware of the increased potential for bleeding, especially from the gastrointestinal tract, during concomitant therapy.
Pindolol Adverse Effect: Decreased antihypertensive effect
Clinical Management: If concurrent therapy is required, monitor the patients blood pressure carefully and assess the need for a dosage adjustment for the beta blocker.
Propranolol Adverse Effect: Decreased antihypertensive effect
Clinical Management: If concurrent therapy is required, monitor the patients blood pressure carefully and assess the need for a dosage adjustment for the beta blocker.
Ramipril Adverse Effect: Decreased antihypertensive and natriuretic effects
Clinical Management: Caution should be used if a nonsteroidal antiinflammatory agent (NSAID) is to be coadministered with an angiotensin converting enzyme (ACE) inhibitor, especially in patients predisposed to or with preexisting nephropathy. Monitor blood pressure and cardiovascular function for a reduction in the efficacy of the ACE inhibitor. Also monitor patient for hyperkalemia or acute renal failure.
Reviparin Adverse Effect: an increased risk of bleeding and an increased risk of hematoma when neuraxial anesthesia is employed
Clinical Management: Patients receiving a low molecular weight heparin and a nonsteroidal antiinflammatory agent (NSAID) concurrently should be monitored closely for bleeding, which may be serious. Gastrointestinal bleeding is a particular concern with this combination, as is the development of a spinal or epidural hematoma in patients who receive epidural/spinal anesthesia or spinal puncture prior to low molecular weight heparin therapy. NSAID therapy should be discontinued several days prior to surgery.
SotalolAdverse Effect: Decreased antihypertensive effect
Clinical Management: If concurrent therapy is required, monitor the patients blood pressure carefully and assess the need for a dosage adjustment for the beta blocker.
Spironolactone Adverse Effect: Reduced diuretic effectiveness, hyperkalemia, or possible nephrotoxicity Clinical Management: When administering Flurbiprofen and Spironolactone concurrently, monitor the patient for decreased effectiveness of the diuretic and hyperkalemia. Monitor blood pressure, weight changes, urine output, potassium levels, and creatinine levels.
Timolol Adverse Effect: Decreased antihypertensive effect
Clinical Management: If concurrent therapy is required, monitor the patients blood pressure carefully and assess the need for a dosage adjustment for the beta blocker.
TinzaparinAdverse Effect: an increased risk of bleeding and an increased risk of hematoma when neuraxial anesthesia is employed
Clinical Management: Patients receiving a low molecular weight heparin and a nonsteroidal antiinflammatory agent (NSAID) concurrently should be monitored closely for bleeding, which may be serious. Gastrointestinal bleeding is a particular concern with this combination, as is the development of a spinal or epidural hematoma in patients who receive epidural/spinal anesthesia or spinal puncture prior to low molecular weight heparin therapy. NSAID therapy should be discontinued several days prior to surgery.
TolbutamideAdverse Effect: a possible increased risk of hypoglycemia
Clinical Management: When nonsteroidal antiinflammatory agents (NSAIDs) are coadministered with a sulfonylurea drug, patients should be monitored more closely for hypoglycemia. Doses of the sulfonylurea may need to be reduced when NSAIDs are added to therapy.
VerapamilAdverse Effect: An increased risk of gastrointestinal hemorrhage
Clinical Management: Patients who are receiving concurrent NSAID and calcium channel blocker therapy should be monitored for signs of gastrointestinal hemorrhage, such as weakness, nausea, and blood in the stool.
Warfarin Adverse Effect: An increased risk of bleeding
Clinical Management: In patients receiving oral anticoagulant therapy with warfarin, the prothrombin time (PT) or international normalized ratio (INR) should be closely monitored with the addition and withdrawal of treatment with nonsteroidal antiinflammatory drugs (NSAIDs), including flurbiprofen. Coagulation parameters should also be reassessed periodically during concurrent therapy. Adjustments of the warfarin dose may be necessary in order to maintain the desired level of anticoagulation. Clinicians and patients should be aware of the increased potential for bleeding, especially from the gastrointestinal tract, during concomitant therapy.
XipamideAdverse Effect: Decreased diuretic and antihypertensive efficacy
Clinical Management: When administering thiazide diuretics and nonsteroidal antiinflammatory agents (NSAIDs) concurrently, monitor blood pressure and weight. Also, follow the patient for decreases in urine output and increased edema. |
|
|